|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2008-3-17
|
|
pubmed:abstractText |
The aim of this study was to compare the cost per unit of effectiveness (successful treatment episode) of 2 highly active antiretroviral therapy combinations-emtricitabine/tenofovir DF + efavirenz (TVD + EFV) and lamivudine/zidovudine + efavirenz (COMB + EFV)-in antiretroviral-naive, HIV-1-infected patients from the perspective of costs to society.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adenine,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzoxazines,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine,
http://linkedlifedata.com/resource/pubmed/chemical/Phosphonic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Reverse Transcriptase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine,
http://linkedlifedata.com/resource/pubmed/chemical/efavirenz,
http://linkedlifedata.com/resource/pubmed/chemical/emtricitabine,
http://linkedlifedata.com/resource/pubmed/chemical/tenofovir
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1879-114X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
372-81
|
|
pubmed:dateRevised |
2009-9-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18343275-Adenine,
pubmed-meshheading:18343275-Anti-HIV Agents,
pubmed-meshheading:18343275-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:18343275-Benzoxazines,
pubmed-meshheading:18343275-Cost-Benefit Analysis,
pubmed-meshheading:18343275-Decision Trees,
pubmed-meshheading:18343275-Deoxycytidine,
pubmed-meshheading:18343275-Drug Costs,
pubmed-meshheading:18343275-HIV Infections,
pubmed-meshheading:18343275-HIV-1,
pubmed-meshheading:18343275-Health Care Costs,
pubmed-meshheading:18343275-Health Resources,
pubmed-meshheading:18343275-Humans,
pubmed-meshheading:18343275-Lamivudine,
pubmed-meshheading:18343275-Models, Economic,
pubmed-meshheading:18343275-Phosphonic Acids,
pubmed-meshheading:18343275-Reverse Transcriptase Inhibitors,
pubmed-meshheading:18343275-Time Factors,
pubmed-meshheading:18343275-Treatment Outcome,
pubmed-meshheading:18343275-Zidovudine
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
|
|
pubmed:affiliation |
Gilead Sciences Inc., Madrid, Spain. rsanchez1968@yahoo.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
